38th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220296587 | Pharmaceutical composition containing alkynyl compound and preparation method and application thereof - The present invention relates to a pharmaceutical composition containing alkynyl compound, a preparation method thereof and its application. The present invention discloses a pharmaceutical composition comprising an active pharmaceutical ingredient and an available pharmaceutical excipient; The active pharmaceutical ingredient is 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-benzamide, or its pharmaceutical acceptable salt; The available pharmaceutical excipients includes diluents and lubricants. The pharmaceutical composition can effectively improve the bioavailability of the alkynyl compound, has good dissolution and stability, and improve the drug safety. | 2022-09-22 |
20220296588 | Pemafibrate Dosing Regimens - To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). | 2022-09-22 |
20220296589 | Formulations of 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, and Methods of Making and Using Same - This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided. | 2022-09-22 |
20220296590 | STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-2-YL)-1-(1H-INDOL-3-YL)-6- ,7-DIHYDRO-3H-OXAZOL[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTITUMOR AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR - The present invention relates to the compounds 3 -(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H -indol-3-yl)-6,7-dihydro-3H-oxazol[3,4-a]pyrazine-5,8-dione of formula (I)), | 2022-09-22 |
20220296591 | ORGANIC COMPOUNDS - The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT | 2022-09-22 |
20220296592 | BROMODOMAIN INHIBITORS TO TARGET THERAPY-RESISTANT CANCER - Novel inhibitors of the bromodomain of Brahma-related gene 1 (BRG1) are described. Also described are methods of treating glioblastoma using inhibitors of the BRG1 bromodomain in combination with chemotherapeutics, such as DNA alkylating agents. As described herein, the inhibitors sensitize glioblastoma cells, including chemoresistant glioblastoma cells, to DNA alkylating agents, for example, temozolomide and carmustine. | 2022-09-22 |
20220296593 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL - The present invention relates to compounds of Table 1, which are encompassed by Formula I and/or Formula II, III, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol. | 2022-09-22 |
20220296594 | POTENTIATORS OF ANTIMICROBIAL AND/OR ANTIVIRAL AGENTS - The present disclosure provides compositions (e.g., pyrimidines) and methods capable of potentiating the effects of antimicrobial agents and/or antiviral agents against bacterial infections and/or viral infections, respectively. Methods of sensitizing bacteria to antimicrobial agents and/or antiviral agents, as well as pharmaceutical compositions and therapeutic/prophylactic methods directed at microbial infections and/or viral infections are also provided. | 2022-09-22 |
20220296595 | CDK INHIBITORS - Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer. | 2022-09-22 |
20220296596 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HAIR LOSS - Compositions and methods for the treatment of hair growth and the prevention of hair loss. | 2022-09-22 |
20220296597 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE - The invention relates to methods for treating chronic lung disease, in particular, alpha-1 antitrypsin deficiency or emphysema resulting from alpha-1 antitrypsin deficiency, with a neutrophil elastase inhibitor. The invention further relates to pharmaceutical compositions comprising a neutrophil elastase inhibitor. | 2022-09-22 |
20220296598 | Poziotinib Combination with VEGFR2 Inhibitors and Methods of Use Thereof - A drug combination containing poziotinib or a pharmaceutically acceptable salt thereof and a VEGFR2 inhibitor and methods of using the combination for treating cancer in a subject in need thereof. The drug combination demonstrates synergistic effect in treating cancers having one or more EGFR or HER2 mutations. | 2022-09-22 |
20220296599 | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate - The present invention relates to a pharmaceutical composition for preventing or treating inflammatory rheumatic diseases, comprising a histone deacetylase inhibitor and methotrexate as an effective component; a treatment method using the composition; and a use of the composition in preparing a drug for treating inflammatory rheumatic diseases, wherein the pharmaceutical composition according to the present invention shows an excellent effect on preventing or treating inflammatory rheumatic diseases. | 2022-09-22 |
20220296600 | USE OF A COMPOSITION COMPRISING 3,6,7-TRIMETHYLLUMAZINE FOR PREVENTING, AMELIORATING OR TREATING MMP-9 ASSOCIATED CONDITIONS AND INFLAMMATION - The invention relates to compositions comprising 3,6,7-trimethyllumazine, methods and uses thereof in preventing, ameliorating or treating inflammation and/or preventing, ameliorating or treating conditions associated with inflammation. More particularly, though not solely, the invention relates to compositions comprising 3,6,7-trimethyllumazine and methods of use thereof in preventing, ameliorating or treating MMP-9 associated conditions, such as inflammation of the gastrointestinal tract and/or inflammatory conditions associated with the gastrointestinal tract. | 2022-09-22 |
20220296601 | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS - Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. | 2022-09-22 |
20220296602 | LIQUID ORAL FORMULATIONS FOR TADALAFIL - The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc. | 2022-09-22 |
20220296603 | PEMETREXED FORMULATIONS - The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C. | 2022-09-22 |
20220296604 | INDOLE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF - Indole compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, schemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity. | 2022-09-22 |
20220296605 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS - Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH). | 2022-09-22 |
20220296606 | NOVEL ANTIVIRAL COMPOSITIONS FOR TREATING THE FLU - The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem. | 2022-09-22 |
20220296607 | TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA - A method and medicament comprising 4,4,4-trifluoro-N-[(IS)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided. | 2022-09-22 |
20220296608 | HETEROCYCLIC RIP1 KINASE INHIBITORS - Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition. | 2022-09-22 |
20220296609 | INDUSTRIAL PROCESS FOR THE PREPARATION OF HIGH PURITY ESTETROL - The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general formula (IV), and to the intermediates of general formulae (III) and (IV) applied in the process. Another aspect of the invention is the use of estetrol of formula (I) obtained by the process of the invention for the preparation of a pharmaceutical composition. | 2022-09-22 |
20220296610 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFECTION AND NOVEL COSMECEUTICAL PREPARATIONS - Disclosed are methods of treating or preventing infection in a mammal in need thereof, by administering the following compound, or related compounds, to a mammal, as well as cosmeceutical preparations and methods of using the same to influence the appearance and/or biological function of the skin by topical application of the preparations comprising the following compound, or related compounds: | 2022-09-22 |
20220296611 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER - A composition according to an embodiment of the present disclosure includes UCDA and a benzimidazole-based compound. A method for treating cancer according to an embodiment of the present disclosure includes administering the composition to a subject in need thereof. The composition has an excellent anticancer effect and has the benefit of having less side effects as cell toxicity of the composition is lower than conventional anticancer drugs used in existing treatments. | 2022-09-22 |
20220296612 | PULMONARY PHARMACEUTICAL FORMULATIONS - The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment. | 2022-09-22 |
20220296613 | FOOD-INDEPENDENT DOSING OF CV-10155 TO TREAT GABAA DISORDERS - The invention provides methods of treating a GABA | 2022-09-22 |
20220296614 | DOSING OF CV-10155 IN THE EVENING OR PRIOR TO SLEEP TO TREAT GABAA DISORDERS - The invention provides methods for treating a GABA | 2022-09-22 |
20220296615 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND SULFONYLUREA COMPOUND - The present invention relates to a combination product comprising a limonoid compound (or a pharmaceutically acceptable derivative, ester, stereoisomer, salt or prodrug thereof), and a sulfonylurea compound (e.g., glibenclamide, gliclazide, glipizide, gliquidone and glimepiride). The present invention further relates to a use of the combination product for prevention and/or treatment of a disease associated with diabetes and the like. | 2022-09-22 |
20220296616 | SHP1 AND SHP2 INHIBITORS AND THEIR METHODS OF USE - Described herein, in one embodiment, are methods of treating neuroinflammation and other disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound described herein, e.g., a SHP1 inhibitor or SHP2 inhibitor, or pharmaceutical composition thereof. | 2022-09-22 |
20220296617 | STABLE LIQUID FORMULATIONS OF CYCLOPHOSPHAMIDE AND PROCESSES TO PREPARE THE SAME - The present invention relates to stable liquid pharmaceutical formulations of cyclophosphamide comprising cyclophosphamide and at least one pharmaceutically acceptable excipient wherein moisture content of the liquid formulation is less than about 2.0% by weight. The invention further relates to stable liquid formulations of cyclophosphamide prepared by a process comprising a step of reducing the moisture content from cyclophosphamide or liquid compositions of cyclophosphamide or both. The invention further relate to method of using such stable liquid formulations of cyclophosphamide for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders. | 2022-09-22 |
20220296618 | ANTI-INFLAMMATORY COMPOUNDS FOR USE IN THE TREATMENT OF DERMAL DISORDERS - The present invention relates to the use of a compound of Formula (I) for the treatment of a wound, impaired healing of a wound, hair loss on and around a wound, scars and/or wrinkles on and around a wound, psoriasis, and any combination thereof. The present inventions also relates to methods of using such compounds, and to compositions and kits containing the compound. (I) X | 2022-09-22 |
20220296619 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE - Long-acting formulations comprising isopropyl ((S)—((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate, or a pharmaceutically acceptable salt thereof, and a biodegradable polymer, e.g. poly(lactic-co-glycolic acid) (PLGA), are described, as are methods of making the long acting formulations and uses thereof. | 2022-09-22 |
20220296620 | AGENT FOR PREVENTING OR TREATING MILD COGNITIVE IMPAIRMENT - An object of the present invention is to provide a substance that can prevent or treat mild cognitive impairment. Mammalian YAP, a polynucleotide encoding mammalian YAP, or a substance capable of increasing an amount of mammalian YAP in a nucleus of a brain neuron is used in the prevention or treatment of mild cognitive impairment. | 2022-09-22 |
20220296621 | FAP-Activated Therapeutic Agents, and Uses Related Thereto - Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer undesirable fibrosis and undesirable inflammation. | 2022-09-22 |
20220296622 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SWI-SNF MUTANT TUMORS - The present disclosure is directed to the use of mithramycin analogs to treat cancers having mutations in the SWI/SNF (SWItch/Sucrose Non-Fermentable) pathway, such as rhabdoid cancers with mutations in SMARCB1 (BAF47, INI1, SNF5), wherein mithramycin analogs comprising EC-8042. Further disclosed are methods of treating cancer comprising treating the subject with a second cancer therapy. | 2022-09-22 |
20220296623 | REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASE - The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of kidney diseases and conditions. In one embodiment of the invention, said compounds and compositions of the invention improve kidney function by reducing formation of kidney cysts, reducing glomerule dilatation, reducing renal cell apoptosis and preventing increases in blood urea nitrogen. In another embodiment of the invention, compounds and compositions of the invention may be used in methods to prevent and/or treat acute kidney injury (AKI), chronic kidney disease, diabetic nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, renal fibrosis and kidney cancer. | 2022-09-22 |
20220296624 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS - Novel selective estrogen receptor degraders (SERDs) according to the formula: | 2022-09-22 |
20220296625 | CANCER CHEMOTHERAPY SUPPORTING AGENT, FOOD, AND DRUG - In order to provide a safe food-derived ingredient that reduces side effects of a cancer chemotherapeutic agent, and particularly to provide a food, a food ingredient (supplement), and a drug that reduce lethal toxic effects of a chemotherapeutic agent, a cancer chemotherapy supporting agent, a food, and a drug according to the present invention are supporting agents for a cancer chemotherapy in which streptozotocin etc., is administered, contain a lipopolysaccharide constituted of | 2022-09-22 |
20220296626 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO - This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether. | 2022-09-22 |
20220296627 | Cytidine Derivatives and Methods of Forming Cytidine Derivatives - Disclosed herein are nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives and methods of forming nucleoside derivatives, cytidine derivatives and Gemcitabine derivatives. | 2022-09-22 |
20220296628 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES - The invention relates inter alia to a combination comprising (i) a first component comprising at least one therapeutic RNA and (ii) a second component comprising at least one antagonist of at least one RNA sensing pattern recognition receptor. Further provided are compositions comprising at least one therapeutic RNA and at least one antagonist of at least one RNA sensing pattern recognition receptor. The combination of the two components is able to reduce immunostimulatory properties of the first component as well as promote expression after administration. Additionally, first and second medical uses, and methods of treating or preventing diseases, disorders or conditions are provided. | 2022-09-22 |
20220296629 | HUMAN HEAD AND NECK CANCER TREATMENT - The present invention is directed to an expression vector and a composition comprising same, wherein the expression includes a precursor of miR-193 a. Further provided are methods of using the expression vector of the invention or the composition comprising same, such as in diagnosing and/or treating head and neck squamous cell carcinoma, in a subject in need thereof. | 2022-09-22 |
20220296630 | STRATEGY TO INCREASE ANTI-VIRAL, ANTI-MICROBIAL, AND ANTI-FUNGAL DEFENSE - Disclosed herein are compositions and methods for inducing, promoting, or enhancing an immune response in a subject. For example, the disclosed compositions and methods can be used prophylactically to prevent viral/microbial infections or therapeutically to treat acute infections. In some embodiments, the disclosed method involves administering to the subject a composition comprising in vitro transcribed (IVT) RNA comprising short interspersed nuclear elements (SINEs), such as Alu repeats. In some embodiments, the disclosed compositions and methods can be used to induce, promote, or enhance any immune response in a subject, including an anti-viral, anti-microbial, anti-fungal, or anti-parasite response. In some embodiments, the disclosed compositions can be administered to any mucosal barrier, such as lungs or intestines, e.g. to enhance an innate immune response against a virus or pathogen. | 2022-09-22 |
20220296631 | METHODS FOR TREATING MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES TO CD49D - A method of modifying muscle or limb performance in a subject with or at risk of a condition associated with muscle atrophy, muscle fatty tissue, or pseudohypertrophy or a muscular dystrophy, by administering a pharmaceutical composition an inhibitory oligonucleotide to CD49d sufficient to modify one or more markers, signs or parameters of muscle fat, muscle performance or function, or limb performance or function. A method comprising the following steps: (i) determining the level of CD4+CD49d+ T cells in a blood sample from the subject; (ii) administering a course of antisense oligonucleotide and repeating step (i) at least once towards the end of the dosing period; (iii) within one week of dose completion repeat step (i); (iv) processing the results to determine whether the subject has or has not displayed a post-dose completion rebound, stability or loss in the level of CD4+CD49d+ T cells. | 2022-09-22 |
20220296632 | MRNA FUNCTIONALIZATION METHOD - The present invention provides a functionalized mRNA including mRNA and double-stranded RNA including at least one RNA oligomer hybridized with mRNA. Functionalized mRNA is provided according to this configuration. | 2022-09-22 |
20220296633 | METHODS FOR TREATING MUSCULAR DYSTROPHY - Methods for treating muscular dystrophy by administering a pharmaceutical composition comprising about 80 to about 300 mg/kg of an antisense oligomer, or pharmaceutically acceptable salt thereof, are described. In one embodiment, the compositions are administered less frequently than occurs in existing methods of treatment | 2022-09-22 |
20220296634 | STABILIZED AQUEOUS COMPOSITION COMPRISING CHONDROITIN SULFATE AND HYALURONIC ACID - The present invention relates to an aqueous composition which comprises chondroitin sulfate, hyaluronic acid, and a pharmaceutically acceptable carrier, and which can be stored at room temperature. | 2022-09-22 |
20220296635 | Compositions Comprising Citrate and Applications Thereof - In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression. | 2022-09-22 |
20220296636 | Carbon Monoxide as a Treatment for Neurodegenerative Disease - Methods for treating neurodegenerative diseases, e.g., Parkinson's disease (PD), with carbon monoxide (CO), e.g., orally administered CO. | 2022-09-22 |
20220296637 | SODIUM THIOSULFATE GEL FOR PREVENTING OR REDUCING HEARING LOSS - Described herein is sodium thiosulfate (STS) for use in preventing or reducing hearing loss in patients receiving platinum-based drugs, for example as chemotherapy to treat cancer. The invention further relates to STS gel compositions suitable for administering to the middle ear of a patient in need thereof, particularly a patient receiving platinum-based drugs. | 2022-09-22 |
20220296638 | METHOD OF TREATING MIGRAINES AND HEADACHES - The disclosure is directed to compositions and methods of treating or preventing headaches, including migraines. The compositions comprise a nitrate anion source, an elemental metal (uncharged), and an acid. The compositions are preferably administered orally. In some aspects, the product of a reaction of the nitrate anion source, the elemental metal (uncharged), and the acid are administered to the subject via inhalation. | 2022-09-22 |
20220296639 | SILVER-/GOLD-COMPOUNDS AND METHODS THEREOF - Disclosed are pharmaceutical compositions containing (a) polymyxin antibiotic and (b) a mobile colistin resistant proteins (MCRs) inhibitor. The inhibitor relates to silver/gold-compounds or the pharmaceutically acceptable salts thereof. Also disclosed are methods of making silver/gold-compounds or the pharmaceutically acceptable salts thereof and methods for treating MCR-producing bacterial infection via multiple mechanisms. | 2022-09-22 |
20220296640 | BIOMARKERS FOR JOINT AILMENTS AND USES THEREOF - The present invention relates to biomarkers that are associated with joint disorders, and methods of using the biomarkers diagnose joint ailments, monitor the progression of joint ailments, determine when treatments is indicated, and monitor the efficiency of treatment. Also provided are methods for treating joint ailments, which comprise administering chelated trace minerals to animals diagnosed with or predisposed to having joint ailments. | 2022-09-22 |
20220296641 | DEAD SEA MINERAL BASED IMPLEMENTATION IN HIGH PERFORMANCE NONWOVEN FABRICS - Provided are nonwoven fabric materials including Dead Sea minerals which exhibit useful aesthetic and physical performance during the time of utilization in a consumer product. Further provided are processes for the preparation of the material and to uses thereof. | 2022-09-22 |
20220296642 | Methods of Making Therapeutic T Lymphocytes - Therapeutic T cells can be prepared from a population of TILs (tumor infiltrating lymphocytes) using tumor and patient-specific neoantigens expressed in antigen presenting cells to select for tumor reactive T cells. Selected tumor reactive T cells are then expanded and administered to the patient. | 2022-09-22 |
20220296643 | METHODS AND COMPOSITION FOR GENE DELIVERY USING AN ENGINEERED VIRAL PARTICLE - The present invention provides compositions and methods for transducing cells (e.g. T cells or immune cells). Also provided herein are methods of treating a disease in a subject in need thereof. | 2022-09-22 |
20220296644 | CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE - Engineered orthogonal chimeric receptor/ligand pairs, and methods of use thereof, are provided. | 2022-09-22 |
20220296645 | DIAGNOSTIC AND THERAPEUTIC USES OF COMPOSITIONS COMPRISING PURIFIED, ENRICHED POTENT EXOSOMES CONTAINING DISEASE-BASED AND THERAPY BASED SIGNATURE CARGO - The present disclosure provides a composition containing a purified and enriched population of potent exosomes derived from extracellular vesicles derived from mesenchymal stem cells (MSCs), a method for diagnosing a human subject aged over 50 years with an age-related chronic disease characterized by disease related dysfunction and optimally treating the subject, and a method for reprogramming a donated organ or tissue comprising a fibrotic disposition including treating the donated organ or tissue with a composition comprising purified enriched population of potent exosomes derived from extracellular vesicles derived from MSCs of a normal healthy subject. | 2022-09-22 |
20220296646 | METHODS AND COMPOSITIONS FOR PURIFICATION OR ISOLATION OF MICROVESICLES AND EXOSOMES - The invention relates to the isolation or extraction of exosomes. | 2022-09-22 |
20220296647 | DIFFERENTIATION INDUCER CONTAINING NUCLEUS PULPOSUS PROGENITOR CELL MASTER REGULATOR TRANSCRIPTION FACTORS, METHOD FOR PRODUCING INDUCED NUCLEUS PULPOSUS PROGENITOR CELLS, AND USE OF INDUCED NUCLEUS PULPOSUS PROGENITOR CELLS - Provided is reproducible means that enables production of nucleus pulposus progenitor cells (preferably, an active nucleus pulposus progenitor cell phenotype) from desired cells such as terminally differentiated cells and stem cells having pluripotency or multipotency. A nucleus pulposus progenitor cell inducer according to the present invention comprising an effective amount of a gene of Brachyury (T) or a homolog thereof, at least one selected from the group consisting of SRY-box6 (SOX6) or a homolog thereof and Forkhead Box Q1 (FOXQ1) or a homolog thereof, and MYC Proto-Oncogene, BHLH Transcription Factor (cMyc) or a homolog thereof (nucleus pulposus progenitor cell master regulator transcription factor), or a product thereof. | 2022-09-22 |
20220296648 | COMPOSITION FOR REGENERATING NUCLEUS PULPOSUS - The present invention provides a composition for regenerating nucleus pulposus and a composition for regenerating an intervertebral disc tissue, each comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients, and a pharmaceutical composition comprising the composition as an active ingredient for preventing or treating a vertebral disease. Simulating features of the nucleus pulposus, such as compression and tensile strength, the composition for regenerating nucleus pulposus can be regenerated into a tissue similar thereto. The composition for regenerating nucleus pulposus can be implanted into an intervertebral disc to restore an injured intervertebral disc tissue. Hence, the pharmaceutical composition comprising same for preventing or treating a vertebral disease can be used as a basic therapeutic agent for a vertebral disease such as a herniated intervertebral disc. | 2022-09-22 |
20220296649 | METHOD FOR PREPARING MATRILIN-3 PRETREATED STEM CELL SPEROIDS, AND COMPOSITION, DERIVED THEREFROM, FOR PREVENTING OR TREATING CARTILAGE DISEASES - Provided are a method of preparing a spheroid of stem cells and a composition including the spheroid prepared by the method, the method including: culturing stem cells in a medium supplemented with matrilin-3 protein; and performing 3D cell culture on the cultured stem cells in the medium. The composition disclosed herein has effects of preventing or treating cartilage disease. In detail, the composition may be able to further promote cartilage differentiation of adult stem cells and reduce dedifferentiation and hypertrophy that may occur during cartilage regeneration, thereby providing a more effective cartilage tissue regeneration method. | 2022-09-22 |
20220296650 | FAT EXTRACT WITHOUT ADDED INGREDIENTS, PREPARATION METHOD THEREFOR AND USE THEREOF FOR GENERATING DROPLET ARRAY ON MICROFLUIDIC CHIP - A fat extract without added ingredients can be used in the preparation of a composition or product for one or more uses amongst (a) promoting proliferation of fibroblasts; (b) promoting anti-aging of fibroblasts; and (c) promoting production of type I collagen in fibroblasts. The preparation method for the fat extract without added ingredients, a pharmaceutical or cosmetic composition containing the fat extract without added ingredients, and a method for culturing fibroblasts in vitro are also provided. The fat extract without added ingredients can effectively and cooperatively inhibit skin aging, prevent fibroblast apoptosis, promote fibroblast proliferation and collagen synthesis, and promote skin rejuvenation. | 2022-09-22 |
20220296651 | XENOGRAFT SOFT TISSUE IMPLANTS AND METHODS OF MAKING - The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes. | 2022-09-22 |
20220296652 | USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS - Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes. | 2022-09-22 |
20220296653 | METHODS FOR LOWERING BLOOD GLUCOSE - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal. | 2022-09-22 |
20220296654 | PROCESSED MICROBIAL EXTRACELLULAR VESICLES - Provided herein are methods and pharmaceutical compositions related to processed microbial extracellular vesicles (pmEVs) that can be useful as therapeutic agents. | 2022-09-22 |
20220296655 | Method and System for Reducing the Likelihood of Developing Colorectal Cancer in an Individual Human Being - A method for reducing the likelihood of an individual developing colorectal cancer includes the use of a CRISPR system to selectively kill pathogenic bacteria, such as | 2022-09-22 |
20220296656 | TREATMENT OF CANCER BY MANIPULATION OF COMMENSAL MICROFLORA - Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments. | 2022-09-22 |
20220296657 | PREVOTELLA PREPARATIONS AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND OTHER LUNG CONDITIONS - This document provides methods and materials related to the treatment of a lung condition, such as chronic obstructive pulmonary disease (COPD), using a composition containing live | 2022-09-22 |
20220296658 | METHODS OF TREATING BLADDER CANCER - The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer. | 2022-09-22 |
20220296659 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF TUMOR OR CANCER, AND APPLICATION THEREOF - Provided are a pharmaceutical composition for treatment of a tumor or cancer, and an application thereof. The pharmaceutical composition comprises an oncolytic rhabdovirus and a small molecule CD38 inhibitor such as rhein that are administered via direct local injection or systemic administration or intratumoral delivery. The oncolytic rhabdovirus has the characteristic of recognizing tumor cells and would not cause damage to normal cells. Meanwhile, the small molecule CD38 inhibitor has the activity of specifically inhibiting T-cell receptor molecules. The combined use of the oncolytic rhabdovirus and the small molecule CD38 inhibitor has significant advantages in safety and efficacy. | 2022-09-22 |
20220296660 | METHODS AND COMPOSITIONS FOR IMPROVING ONCOLYTIC VIRUS INFECTION FOR NONPERMISSIVE CANCERS - Disclosed herein are methods and compositions of treating cancer, comprising administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a nucleocytoplasmic transport inhibitor. Further described herein are methods of converting a nonpermissive cancer cell to a permissive cancer cell and methods of killing a cancer cell by contacting the cancer cell with a therapeutically effective amount of an oncolytic vims and a nucleocytoplasmic transport inhibitor. | 2022-09-22 |
20220296661 | PROCESSES FOR PRODUCING OMEGA-3 CONTAINING COMPOSITIONS FROM ALGAE AND RELATED EXTRACTIONS - A method for producing highly bioavailable oil compositions from biomasses and, in particular, autotrophic algal biomasses, and providing characterized and clarified mass balance breakdowns and component products therefrom without loss of significant mass in an extraction such as a liquid-liquid extraction, polarity segregation and use of mechanical cartridges. | 2022-09-22 |
20220296662 | COMPOSITIONS AND METHODS FOR PROMOTING A HEALTHY MICROBIAL FLORA IN A MAMMAL - The disclosure provides compositions and dosage forms for promoting healthy microbial flora in a mammal, for example, a human. The disclosure further provides compositions and dosage forms for disrupting biofilm or preventing formation of biofilm containing pathogenic bacteria and/or pathogenic fungi in a particular region of a subject. The dosage forms contain (i) an isolated non-pathogenic fungal strain that is viable in the region of the subject, (ii) an isolated non-pathogenic bacterial strain that is viable in the region of the subject, and optionally (iii) an enzyme capable of disrupting the biofilm. The present disclosure also provides methods of disrupting a biofilm or preventing formation of a biofilm with such a composition or dosage form, methods of identifying a subject suitable for treatment with such a composition or dosage form, and methods of improving nutrient absorption using such a composition or dosage form. | 2022-09-22 |
20220296663 | PRE-MOISTENED WIPES FOR USE IN TREATING ANAL RECTAL IRRITATIONS AND DISORDERS - Many people who suffer from anal rectal discomfort and disorders need fibrous sheet materials which are pre-moistened with a solution for improved cleansing without excessive skin irritation. The invention particularly concerns wet wipes, such as anal-rectal wipes, which comprises a solution comprising | 2022-09-22 |
20220296664 | THE TOPICAL COMPOSITION WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND CALENDULA OFFICINALIS FOR REDUCTION OF SKIN LESIONS - Disclosed is a method of treatment using a topical composition including essential sombination of synergistically acting phyto-active materials, non-psychotropic phtocannabinoids from the plant of | 2022-09-22 |
20220296665 | FUNCTIONAL FOOD COMPOSITION FOR ALLEVIATION OF IRRITABLE BOWEL SYNDROME - A functional food composition contains a | 2022-09-22 |
20220296666 | COMPOSITIONS AND METHODS OF PRODUCING DE-FLAVORED PEPPERCORN - Disclosed herein are compositions and methods for de-flavoring a peppercorn, whole or ground, that minimize piperine, a naturally occurring alkaloid imparting pungency, that minimize volatile oils imparting aroma, and that retain most of the naturally occurring metabolic micronutrients. A method is also disclosed that includes contacting a peppercorn with one or more oils thereby producing a de-flavored peppercorn. | 2022-09-22 |
20220296667 | COMPOSITION FOR ALLEVIATING AND TREATING NARCOLEPSY, CONTAINING FERMENTED RICE BRAN POWDER AS ACTIVE INGREDIENT, AND PREPARATION METHOD THEREFOR - A composition for alleviating and treating narcolepsy, contains a fermented rice bran powder as an active ingredient. The fermented rice bran powder can be obtained by mixing rice bran with a specific strain and fermenting the resulting mixture, and the composition exhibits cranial nerve stimulation and causes no cognitive impairment, thereby exhibiting an effect of waking a sleeping person, and thus can solve psychological and social problems caused by excessive daytime sleepiness and prevent feelings of shame, difficulty in interpersonal relationships, a decline in work performance and a risk of accidents. In addition, the composition is not neurocytotoxic, and thus can achieve only a desired effect without side effects. | 2022-09-22 |
20220296668 | HIGHLY CONCENTRATED FORMULATIONS OF SOLUBLE Fc RECEPTORS - The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc | 2022-09-22 |
20220296669 | NOVEL COMPOSITIONS AND USES THEREOF - The present invention provides a composition comprising: (a) collagen VI or a polypeptide comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof; and (b) polylysine. Also provided are pharmaceutical compositions and kits comprising the composition of the invention. Related aspects provide medical devices, implants, wound care products and materials for use in the same associated with the composition of the invention, and methods of their preparation. Also provided are methods and uses of the composition in the treatment and/or prevention of microbial infections and in wound care, and a method of killing microorganisms in vitro. | 2022-09-22 |
20220296670 | NEW COMPOSITION CONTAINING BRANCHED-CHAIN AMINO ACIDS - The present invention relates to compositions comprising branched-chain amino acids (BCAA) and the dipeptide L-Alanyl-L-alanine and their use for improving the performance and recovery during physical activity and for the prevention and/or treatment of muscle wasting associated to pathological or age-related conditions. | 2022-09-22 |
20220296671 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING - The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2. | 2022-09-22 |
20220296672 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY - The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition. | 2022-09-22 |
20220296673 | METHOD OF ENHANCING A BRAIN OR COGNITIVE FUNCTION - A composition for improving memory, learning ability, and cognitive ability and a method of enhancing a brain or cognitive function by administering the composition to a subject in need thereof. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least 4 amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability, and the method of enhancing a brain or cognitive function. | 2022-09-22 |
20220296674 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - The inventors have identified a novel cell-penetrating sequence, termed hAP | 2022-09-22 |
20220296675 | SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs). | 2022-09-22 |
20220296676 | TREATMENT OR PREVENTION OF CORONAVIRIDAE INFECTION - A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus, | 2022-09-22 |
20220296677 | PEPTIDE SCYREPROCIN OF SCYLLA PARAMAMOSAIN AND METHOD THEREOF - A peptide Scyreprocin of | 2022-09-22 |
20220296678 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES - The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate. | 2022-09-22 |
20220296679 | TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - The present invention relates to methods of treating chemotherapy-induced peripheral neuropathy. In particular, the methods provide a new way of reducing neuropathic pain associated with chemotherapy-induced peripheral neuropathy by administering a nucleic acid construct encoding human HGF proteins. This application further provides nucleic acid constructs, pharmacological compositions, and methods of administration of the nucleic acid constructs that are effective in treating the neuropathic pain. | 2022-09-22 |
20220296680 | TREATMENT AND PREVENTION OF CARDIORENAL DAMAGE - The present disclosure provides compositions and methods for treatment and prevention of cardiorenal damage. In particular, provided herein are compositions comprising proANP | 2022-09-22 |
20220296681 | INHIBITION OF METASTASIS DEVELOPMENT BY NANGPTL-4 - The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer. | 2022-09-22 |
20220296682 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES - The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L | 2022-09-22 |
20220296683 | ORAL DELIVERY SYSTEM - The invention provides a method of preparing a silica-protein sub-micron particle, the method comprising contacting, in an aqueous medium having a pH in the range of about 7.5 to 10 and having an ionic strength in the range of about 1.2 to 60 mM, (i) protein sub-micron particle cores comprising 0.2 to 3 μmoles, per mg of the protein sub-micron particle cores, of a basic compound of formula (I) or an ester and/or amide thereof wherein n is an integer selected from 1 to 10, and p is an integer selected from 1 to 3, with (ii) orthosilicic acid or an ester thereof, in an amount equivalent to 5 to 60% (w/w) orthosilicic acid per mg of the protein sub-micron particle cores, to form the silica-protein sub-micron particle. The invention also provides a method of making a GLP-1 receptor agonist sub-micron particle core, by a. contacting a peptide in an aqueous medium at a pH of about 5.0-8.0 and comprising about 0.3-1.3 mM peptide, wherein the peptide is a GLP-1 receptor agonist, with the above-mentioned basic compound of formula (I) or an ester and/or amide thereof: wherein n is an integer selected from 1 to 10, and p is an integer selected from 1 to 3; in a molar ratio between the peptide and the basic compound of from 1:about 20 to 1:about 90 to form a step a. reaction mixture having a pH of about 7.5 to 10.0; optionally about 9.5; b. contacting the step a. reaction mixture with zinc to form a step b. reaction mixture, wherein the ratio of peptide:basic compound:zinc in the step b. reaction mixture is 1:about 20 to 110:9 to 30; whereby the GLP-1 receptor agonist sub-micron particle core is formed. The invention also provides a method of making an insulin sub-micron particle core, the method comprising the steps of: a. contacting insulin in an aqueous medium having a pH of less than about 6.0 and comprising about 0.50 to about 1.50 mg/mL insulin, with the aforementioned basic compound of formula (I) or an ester and/or amide thereof; in a molar ratio between the insulin and the basic compound of from about 1:40 to about 1:140 to form a step a. reaction mixture having a pH of about 7.5 to 10; b. contacting the step a. reaction mixture with zinc to form a step b. reaction mixture, wherein the molar ratio of insulin:zinc in the step b. reaction mixture is 1:about 0.5 to about 10; whereby the insulin sub-micron particle core is formed. | 2022-09-22 |
20220296684 | METHOD OF TREATMENT FOR HAIR LOSS - Micronutrient compositions for treating hair loss, and methods for treating hair loss by periodically administering the compositions. The micronutrients include vitamins, antioxidants, minerals, such as ferrous, calcium, and zinc salts, amino acids, fatty acids, co-enzyme Q10, biotin, omega 3, B-complex, curcumin, colostrum, lactoferrin, N acetyl cysteine, inositol, melatonin, biotin, and the like, and combinations thereof. Careful selection of doses and dosing schedules allows enhancing efficiency, preventing antagonism, reducing side effect and avoiding wastage and overdose of the micronutrients. The components support the activity of the hair growth cycle, and act as building blocks required for hair growth, lack of which can lead to slowing down and arrest of hair growth. They also help maintain inter- and intra-cellular calcium levels, reduce interference with glucose metabolism, gastric irritation and constipation in patients, and promote hair growth, without using Minoxidil or Finasteride. | 2022-09-22 |
20220296685 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG - A uricase derivative co-conjugated with fatty acid-linked polyethylene glycol derivatives and optionally, alkoxy polyethylene glycol derivatives is presented. The uricase may be intramolecularly crosslinked. The uricase derivative of the present invention is intended for use as a treatment for gout or hyperuricemia. | 2022-09-22 |
20220296686 | THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINS - The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment. | 2022-09-22 |